

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/127500/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Barber, Paul R., Weitsman, Gregory, Lawler, Katherine, Barrett, James E., Rowley, Mark, Rodriguez-Justo, Manuel, Fisher, David, Gao, Fangfei, Tullis, Iain D.C., Deng, Jinhai, Brown, Louise, Kaplan, Richard, Hochhauser, Daniel, Adams, Richard, Maughan, Timothy S., Vojnovic, Borivoj, Coolen, Anthony C.C. and Ng, Tony 2020. HER2-HER3 heterodimer quantification by FRET-FILM and patient subclass analysis of the COIN colorectal trial. JNCI: Journal of the National Cancer Institute 112 (9), pp. 944-954. 10.1093/jnci/djz231

Publishers page: <https://doi.org/10.1093/jnci/djz231>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



HER2-HER3 heterodimer quantification by FRET-FLIM and patient subclass analysis of the COIN colorectal trial

Paul R Barber PhD ^{1*}, Gregory Weitsman PhD ^{2*}, Katherine Lawler PhD ^{2,3*}, James Barrett PhD ², Mark Rowley PhD ^{3,4}, Manuel Rodriguez-Justo MB ChB ¹, David Fisher MSc ⁵, Fangfei Gao MB BChir¹, Iain D C Tullis PhD ⁶, Jinhai Deng BSc ², Louise Brown PhD ⁵, Richard Kaplan PhD⁵, Daniel Hochhauser BA MBBS MRCP DPhil ¹, Richard Adams BMedSci BMBS MRCP FRCR MD ⁷, Timothy S Maughan FMedSci ⁶, Borivoj Vojnovic PhD ⁶, Anthony CC Coolen PhD ^{3,4}, and Tony Ng MBChB MRCP FRCPath PhD ^{1,2,8†}

1. UCL Cancer Institute, Paul O’Gorman Building, University College London, London WC1E 6DD

2. Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King’s College London, London, UK, SE1 1UL

3. Institute for Mathematical and Molecular Biomedicine, King’s College London, Guy’s Medical School Campus, SE1 1UL

4. Saddle Point Science Ltd, London, UK

5. MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, Aviation House, 125 Kingsway, London WC2B 6NH

6. Department of Oncology, Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, University of Oxford, Oxford, OX3 7DQ

7. School of Medicine, Cardiff University, Cardiff, UK

8. Breast Cancer Now Research Unit, Department of Research Oncology, Guy’s Hospital King’s College London, London, SE1 9RT

*These authors made an equal contribution to this article.

†To whom correspondence should be addressed:

Prof. Tony Ng

Tel no: +44 (0) 20 7848 8056 (KCL)

E-mail: tony.ng@kcl.ac.uk, t.ng@ucl.ac.uk

List of abbreviations:

<i>AREG</i>	amphiregulin
EGFR	Epidermal growth factor receptor
<i>EREG</i>	epiregulin
FLIM	Fluorescence Lifetime Imaging Microscopy
FRET	Förster Resonance Energy Transfer
LCA	Latent Class Analysis
mCRC	Metastatic Colorectal Cancer
MRC	Medical Research Council
OS	Overall Survival
PFS	Progression Free Survival
TRT	Treatment
WT	Wildtype

ABSTRACT

Background: The phase 3 MRC COIN trial showed no statistically significant benefit from adding the EGFR-target cetuximab to oxaliplatin-based chemotherapy in first-line treatment of advanced colorectal cancer. This study exploits additional information on HER2-HER3 dimerization to achieve patient stratification and reveal previously hidden subgroups of patients who had differing disease progression and treatment response.

Methods: HER2-HER3 dimerization was quantified by “FLIM Histology” in primary tumor samples from 550 COIN trial patients receiving oxaliplatin and fluoropyrimidine chemotherapy +/-cetuximab. Bayesian latent class analysis (LCA) and covariate reduction was performed to analyze the effects of HER2-HER3 dimer, *RAS* mutation and cetuximab on progression-free survival (PFS) and overall survival (OS). All statistical tests were two-sided.

Results: LCA on a cohort of 398 patients revealed two patient subclasses with differing prognoses (median OS: 1624 days [95%CI=1466-1816] vs 461 [95%CI=431-504]): Class 1 (15.6%) showed a benefit from cetuximab in OS (HR=0.43 [95%CI=0.25-0.76]; p=0.004). Class 2 showed an association of increased HER2-HER3 with better OS (HR=0.64 [95%CI=0.44-0.94]; p=0.02). A class prediction signature was formed and tested on an independent validation cohort (N=152) validating the prognostic utility of the dimer assay. Similar subclasses were also discovered in full trial dataset (N=1,630) based on 10 baseline clinicopathological and genetic covariates.

Conclusions: Our work suggests that the combined use of HER dimer imaging and conventional mutation analyses will be able to identify a small subclass of patients (>10%) who will have better prognosis following chemotherapy. A larger prospective cohort will be required to confirm its utility in predicting the outcome of anti-EGFR treatment.

The selection of patients who are likely to benefit from treatment with an EGFR inhibitor with first line chemotherapy for metastatic colorectal cancer (mCRC) remains controversial. Two major trials have compared the addition of cetuximab or bevacizumab for patients with *KRAS* wildtype colorectal cancer [1-3]. FIRE-3 showed a statistically significant survival benefit from cetuximab, in contrary to the US-based CALGB 0405 study, leading to intense debate [4]. Results show markedly improved overall survival (OS) compared to older trials, partially driven by the selection of the better prognosis *KRAS* wildtype population. The presence of any *extended* RAS mutation [5] was demonstrated to exclude patients from benefit of panitumumab in the PRIME trial; this is now enshrined in license [6].

Other molecular factors also influence responsiveness to the addition of an EGFR inhibitor: the presence of a *BRAF* mutation and low expression of key EGFR ligands, epiregulin (*EREG*) or amphiregulin (*AREG*), both predict a lack of benefit [7, 8]. The primary tumor's site of origin is also important. Tumors arising from the right, midgut derived, colon, falling in the arterial supply of the superior mesenteric artery, are more frequently methylated (with resulting low expression of EGFR ligands) [9-11], more often have mismatch repair deficiency, and carry a *RAF* mutation [12-14]. Left-sided cancers more often exhibit those features of responsiveness to EGFR treatment, namely high ligand expression and *RAS* and *RAF* wildtype. Initial reports also indicated that *PIK3CA* mutations may be associated with diminished responsiveness but these conclusions were from small studies (2-11 patients with *PIK3CA* mutations) [15, 16]. Larger studies did not show a statistically significant difference [17, 18], with the exception of one study showing that *PIK3CA* exon 20 mutation confers a poorer outcome [19]. Despite all this, reliable methods for the identification of patients who may benefit from EGFR antibody therapy remain elusive.

In this paper we describe a novel approach to this problem. It is known that HER (ErbB) mediated signaling is initiated following dimerization between the same (homodimerization) or different HER family members (EGFR, ErbB/HER1-4) [20]. Dimers containing HER3, especially the HER2-HER3 heterodimer, have been shown to provide the

most potent proliferative signal to cancer cells [21]. Recently, we showed in preclinical experiments the HER2-HER3 can be modulated upon cetuximab treatment of colorectal cancer cells [22]. The same heterodimer has been demonstrated using archived primary breast cancer samples and contains statistically significant prognostic information which is independent of that of HER2 receptor expression status [23]. It is usually difficult to determine whether the receptors are forming dimers but the technique of Förster Resonance Energy Transfer (FRET) reports on the immediate proximity, only achieved during dimerization. The combination of FRET with time-domain Fluorescence Lifetime Imaging Microscopy (FLIM) allows the minute fluorescence signals to be detected [24]. Hence FRET-FLIM represents the most exquisitely sensitive method for determining what proportion of a receptor is dimerized.

Here we report the use of “FLIM Histology”, a technique using FRET-FLIM as a measure of the proportion of receptors in the HER2-HER3 dimer state, a concentration independent parameter, based on a well-established gold standard technique to probe endogenous protein-protein interactions in cells [23, 25-30]. In 550 patients from the MRC COIN trial [31], combining the use of HER dimer measurement and recently reported Bayesian statistical methods [32-34], we aimed to identify subclasses of patients with different prognostic outcomes.

MATERIALS AND METHODS

Patients and Treatment

In the MRC COIN trial (ISRCTN79877428) [31] patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease (RECIST v1.0), and were fit for first line combination chemotherapy, were randomized in a 1:1:1 ratio to receive the control arm of continuous oxaliplatin-based chemotherapy (A), or continuous chemotherapy plus cetuximab (B), or intermittent

chemotherapy (C). This study was restricted to arms A and B. Two chemotherapy regimens, XELOX or OxMdG (oxaliplatin with modified deGramont, a FOLFOX variant), were used.

Objectives and Outcome Measures

The primary objective of the COIN A vs B comparison was to determine whether the addition of cetuximab to continuous chemotherapy resulted in improved outcome in patients with *KRAS* wildtype (WT) tumors. Overall Survival (OS) was calculated as time from randomization to death from any cause. Survivors were censored at the last known alive date. Progression Free Survival (PFS) was calculated as the interval from randomization to first evidence of progression or death from any cause. Survivors without progression were censored at the last known alive date.

Patient Samples and Imaging

This study was approved by the Trial Steering Committee and FRET-FLIM was limited to those patients who had given written informed consent for 'other bowel cancer research', in whom sufficient residual pathological specimen was available.

Patient tissue micro-arrays (TMAs) were retrieved from the Wales Cancer Bank and processed at King's College London. Two consecutive slices of all TMAs underwent antigen retrieval in a Ventana BenchMark system and were stained with anti-HER3-IgG-Alexa546 ('donor' or 'D' slice) and in addition with anti-HER2-IgG-Cy5 ('donor with acceptor' or 'DA' slice) and mounted as described previously [26].

TMA slices were imaged on an "open" automated FLIM microscope [35]. FLIM analysis was performed with the TRI2 software (v2.7.8.9, CRUK/MRC Oxford Institute for Radiation Oncology, Oxford) [36-38]. Autofluorescence effects were minimized with a lifetime filtering algorithm [39]. The FRET efficiency for each tissue region was calculated according to $\text{FRET efficiency} = 1 - (\tau_{DA}/\tau_D)$, where τ_D and τ_{DA} are the average lifetime of Alexa546 in the matching D and DA images respectively. FRET efficiency (denoted:

“FRET”), and FRET efficiency multiplied by HER3 fluorescence intensity, representing the amount of dimerized HER3, (“FRET x HER3”) were calculated as continuous variables (**Supplementary Figure 1**).

The use of formol saline fixation, as opposed to neutral buffered formalin, resulted in excessive amounts of contaminating autofluorescence. These samples (292 patients) were excluded.

TMA from the 398-patient training set and the 152-patient validation set were received and processed independently in two batches. All analysis of the training set was performed before the validation TMA was received, and was therefore performed completely blind and without knowledge of the validation set.

Statistical Analysis

Bayesian latent class analysis (LCA) was performed using the model described by Rowley et al. [32] (ALPACA v0.2.15), which seeks to detect and map association and base hazard rate heterogeneity. This results in objective cohort stratification, driven strictly by observed and statistically significant regularities in the data. Specification of the number of latent classes and the complexities of class-dependent base hazard rates, is based on Bayesian model selection. Patients were retrospectively assigned to latent groups according to maximum *a posteriori* class membership probability.

Covariate reduction and the generation of predictive signatures was performed by Bayesian multivariate survival analysis with repeated cross-validation and backwards elimination with the aim of reducing overfitting [33].

Kaplan-Meier plots and log-rank statistics were produced using the R ‘survival’ package (v2.42-3, R v3.5.1). When $p < 0.05$ the result was considered statistically significant and all tests were two-sided.

RESULTS

Tissues from two cohorts of 398 and 152 patients (the 'FRET' training and validation cohorts respectively) were analyzed for HER2-HER3 dimerization. All patients also formed a 'full' cohort of 1,630 patients. **Figure 1** summarizes the patient selection for imaging and analysis and **Table 1** contains the cohort patient characteristics. A continuous distribution of FRET efficiency with a mean value of 1.6%, (lower quartile 0.18%, upper quartile 2.7%) was recorded. **Figure 2** shows typical images and FRET efficiency maps.

LCA was performed on the FRET training cohort for both outcomes using, a minimal, 4 covariates: FRET; FRET x HER3 (since HER protein concentration information is independent of dimer [40]); Treatment Arm (to give the algorithm the ability to detect groups with different responses); and *RAS* mutation status (because of its known association with cetuximab treatment).

We report evidence of two novel latent classes in the 398-patient training set, with both PFS and OS analysis. The hazard ratios (HR) assigned to each covariate for each class is shown in **Figure 3A-B**. Based on PFS, 44/398 (11.1%) of patients were retrospectively assigned to Class 1, the remainder to Class 2; for OS 62/398 (15.6%) were assigned to Class 1. **Figure 3C-D** shows Kaplan-Meier plots split by class and treatment (TRT). Class 1 patients had a better prognosis (median OS: 1624 days [95%CI=1466-1816] vs 461 [95%CI=431-504]) and a predictive response to cetuximab which was more pronounced in OS: Class 1 TRT HR=0.43 [95%CI=0.25-0.76] logrank p=0.003 (median OS: 1447 days vs 1668 days; difference = 221 days, see Supplementary Methods for more details). This is statistically significantly larger than among all patients in the cohort (median OS: 505 days vs 581 days; difference = 76 days).

The second and consistently larger group (Class 2) did not show a statistically significant benefit from cetuximab (PFS: HR=0.93 [95%CI=0.69-1.25], p=0.62, OS: HR=1.03 [95%CI=0.74-1.42], p=0.88), however, increased FRET efficiency was associated with improved outcome (PFS: HR=0.63 [95%CI=0.46-0.88], p=0.006, OS: HR=0.64

[95%CI=0.44-0.94], $p=0.02$) (**Figure 3A,C**). **Figure 3E-F** shows Kaplan-Meier curves split by class and FRET demonstrating the benefit of cetuximab to those with a high FRET score. FRET x HER3 did not have a statistically significant HR.

Table 2 shows the characteristics of the patient classes and gives an indication of which parameters may be useful in a prospective patient classifier ($p<0.05$): FRET (**Supplementary Figure 2**), liver-only metastases, *PIK3CA* mutation status, RECIST sum of longest diameter, neutrophil count, white blood cell count, pain at baseline, haemoglobin and alkaline phosphatase.

Additional LCA was performed without the FRET parameters and determined that there was insufficient evidence for distinct latent groups. The HER2-HER3 FRET efficiency data therefore conveys ~~significant~~ additional information.

As validation of this class structure we sought further evidence in the full COIN cohort (1,630 patients, including FRET cohorts) for whom clinical and genomic data was available. To maximize the utility of any findings for patient stratification we performed analysis with all available baseline covariates (115 covariates including missingness indicators, expanded categorical data and TRT, see **Supplementary Methods**). These were subject to Bayesian covariate reduction against OS and we identified a signature that combined 10 covariates (WHO performance status, previous adjuvant chemotherapy status, RECIST sum of longest diameter, number of metastatic sites, *EREG*, *RAS* status (*KRAS* or *NRAS*), *BRAF* status, neutrophil count, alkaline phosphatase and pain).

These 10 covariates, plus TRT, in the full cohort were subject to OS-based LCA which revealed that three classes were most likely (**Figure 4A**). Class 1 (N=93/1630) indicates a possibility of a positive response to cetuximab (HR=0.71 [95%CI=0.45-1.14], $p=0.16$), Class 2 (N=350/1630) shows no response (HR=0.94 [95%CI=0.70-1.25], $p=0.66$) and Class 3 (N=1187/1630) shows a statistically significant negative response (HR=1.34 [95%CI=1.10-

1.71], $p=0.005$). This is reflected in the Kaplan-Meier curve split by class and TRT (**Figure 4B**). PFS-based LCA did not reveal interesting classes.

To investigate the overlap in membership of individual patients between the classes of the two LCA analyses from the FRET cohort and the full cohort, the class membership table for the 398 FRET cohort patients is presented in **Figure 4C**. A permutations test (100,000 random permutations of 398 patients into classes in these proportions) indicated a probability of $<1/100,000$ for obtaining this overlap in membership by chance. LCA was also performed on the non-overlapping set of 1,232 patients (1,630 minus 398) and a similar three groups were found (See **Supplementary Figure 3**).

In the FRET cohort there was a statistically significant association of *PIK3CA* mutation with better OS (median 875 vs 504 days, logrank $p=0.03$, **Supplementary Figure 4**), which agrees with the observation of a higher proportion of *PIK3CA* mutant in the responding Class 1. This association was not detectable in the full cohort. A breakdown into exon 9 or exon 20 *PIK3CA* mutation groups did not reveal any statistically significant differences in PFS or OS, in either cohort (FRET cohort: exon 9, $N=37/398$, exon 20, $N=12/398$; full cohort exon 9, $N=106/1630$, exon 20, $N=50/1630$).

To form a covariate signature that may predict class membership we performed Bayesian covariate reduction on the union of the nine covariates identified in **Table 2** and the 10 prognostic baseline covariates: total 15. The resulting signature contained seven statistically significant covariates (RECIST sum of longest diameter, neutrophil count, white blood cell count, haemoglobin, *PIK3CA* mutation status, liver-only metastases and FRET) with associated weights (**Figure 5A**).

The performance against the LCA class assignment of the 398 is shown in **Figure 5B** (AUC: 0.753). The signature was used as a classifier, by selecting an optimal point on the ROC curve (according to Youden's index) with specificity of 0.677 and sensitivity of 0.708. The results on the 398 training set and the independent validation set of 152 are shown in

Figure 5C-D with survival curves split by class and treatment. The re-classification of the 398 patients using the new signature-based classifier clearly retains the prognostic ($p=0.001$, chemo only patients) and predictive ($p=0.04$) elements of the classes. In the 152-patient validation set we again recreate the prognostic behavior ($p=0.04$ (both TRT arms), $p=0.09$ (chemo only patients)).

Another signature was produced without FRET (from 14 parameters, **Figure 5E**) and **Figure 5F-G** demonstrate that the with-FRET signature has prognostic power in the validation set, where the without-FRET signature does not. The interplay of FRET with the other covariates is explored in **Supplementary Figure S5**.

DISCUSSION

The selection of patients for EGFR-inhibitor treatment for mCRC remains difficult. With *KRAS* WT patients, the addition of EGFR-targeted treatment (cetuximab/panitumumab) to irinotecan or oxaliplatin chemotherapy [1, 6, 41, 42], is associated with a statistically significant survival benefit in three of four phase 2/3 trials [1, 6, 42]. However, the improvement of median PFS was only around 1-2 months. In the phase 2 OPUS trial, addition of cetuximab to FOLFOX4 resulted in a statistically significant improvement in PFS (8.3 months vs 7.2 months, $p=0.006$) [42]. In contrast, the NORDIC VII trial reported no benefits from adding cetuximab to oxaliplatin-based regimen (with bolus 5-FU) [41]. EGFR immunohistochemistry is not a sufficient predictive factor for clinical benefit for cetuximab in the *KRAS* WT population [43, 44].

Further molecular stratification by identifying novel subgroups will make a meaningful contribution towards assessing the efficacy of EGFR targeting in future clinical trials. Here we present the application of our recently improved and validated [23] FLIM Histology analysis method for quantification of HER2-HER3 dimer in FFPE samples from the randomized phase 3 MRC COIN trial. Using FLIM-based molecular imaging parameters and a recently published Bayesian statistical method [32] we have shown that there are two

classes of patients with mCRC Table 2, Figure 3. Class 1 (10-15% of patients) had a better prognosis and also benefited from addition of cetuximab to the standard chemotherapy. Within Class 2 (85-90% of patients), patients have less favorable survival (median PFS circa 7.5 months) and no benefit from cetuximab.

To validate these results we formed a biomarker that predicts class membership by creating a novel signature of seven parameters that were pre-determined by the two Bayesian latent class analyses. This was applied to the training set of 398 and we retained the predictive and prognostic elements of, the smaller, Class 1. Notably, the prognostic effect on survival (195 days, comparing chemotherapy only patients between Classes 1 and 2) was larger than the predictive effect (136 days, comparing Class 1 patients with/without cetuximab). Application of the signature to the completely independent validation set of 152 patients was sufficient to validate the prognostic (but not the predictive) utility. In addition, we found that patients exhibiting a high FRET value are more likely to be in the worst prognostic outcome subclass i.e. Class 2 (Table 2) as reflected in the class prediction signature (Figure 5A). However, within Class 2 a high FRET value can be indicative of better outcome within that class dependent on the other signature covariates. Importantly, the class prediction (seven-parameter) signature is entirely dependent on the inclusion of the HER2-HER3 dimer quantity.

We chose HER2-HER3 because it has been shown to be the most tumor promoting dimer among EGFR family members, due to its downstream activation of PI3-kinase (PI3K)/AKT and MAPK pathways [45-47]. Secondly, the mRNA expression of alternative ligands such as EREG, which has been shown to modulate the efficacy of EGFR-targeted agents in *KRAS* WT mCRCs [7], is the broadest specificity EGF-like ligand that induces the widespread phosphorylation of HER1-4 [48]. Although the mechanism of this modulation is not precisely known, EREG, as opposed to EGF, can recruit HER3 into heterodimers, as reflected by its enhancement on the proliferative activity on cells co-expressing a combination of HER3 with either HER2 or HER4 [49]. Thirdly, we showed by FRET-FLIM

imaging, an induction of HER2-HER3 dimers after cetuximab treatment in *KRAS* and *BRAF* WT colon cancer cells [22].

The additional HER2-HER3 dimer parameter as measured by FLIM may be important for the future stratification of anti-HER2 treatment combination using pertuzumab plus trastuzumab [50]. Notably, HER2 activity (of prognostic signature) has been shown previously to be measurable by FLIM independently of HER2 concentration [23].

This new retrospective analysis suggests that the proportion of patients gaining benefit from cetuximab may be as small as 10% and concurs with clinical data that these patients are amongst those with the best baseline prognosis. HER2-HER3 FRET-FLIM provided new information enabling the statistical method to identify this latent class. This hypothesis generating data shows the potential of measurement of dimers and demonstrates the utility of FRET-FLIM to assess dimerization in FFPE tissue.

Further preclinical experiments, using patient derived organoids for example, are needed to understand the statistically significantly increased prevalence of *PIK3CA* mutations in the discovered Class 1. Previously anti-EGFR response was shown to be higher for *RAS* WT patients who expressed pEGFR and pAkt [51]. pAkt may in turn be linked to EGFR trafficking and degradation, and therefore treatment response, warranting further study [52]. Furthermore, the predictive utility of this assay may be further enhanced by the inclusion of pre- and post-treatment dimer measurements as we have recently demonstrated in a Phase 2 head and neck study using an exosomal HER dimer assay [53].

In conclusion, this study demonstrates how a novel Bayesian LCA, signature generation and covariate reduction can be used as objective approaches to generate hypotheses for treatment. Given that the identification of prognostic and predictive biomarkers and clinical characteristics in colorectal cancers is an active area of research, this study shows how the development and application of statistical methods contributes to the retrospective analysis of trials. The ability to model and quantify the evidence for putative

patient stratifications is therefore a crucial initial step towards identifying and validating strategies for targeting therapies.

FUNDING

This work was supported by the CRUK UCL Centre (C416/A25145), CRUK City of London Centre (C7893/A26233) and CRUK KCL-UCL Comprehensive Cancer Imaging Centre (CRUK & EPSRC) in association with the MRC and DoH (C1519/ A16463 and C1519/A10331); KCL Breast Cancer Now Unit (KCL 06/07); EU FP7 IMAGINT (EC: 259881); and Science Foundation Ireland (06/CE/B1129). We are grateful for the use of tissue samples and data from the COIN trial, funded by the MRC, Cancer Research UK (grant C1210/A4850) and Merck Serono, and coordinated by the MRC Clinical Trials Unit at UCL.

NOTES

The funders had no role in the study design, the collection, analysis and interpretation of the data, the writing of the manuscript and the decision to publish.

Author Affiliations

UCL Cancer Institute, University College London, UK (PRB, MR-J, FG, DH, TN); Richard Dumbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK (GW, KL, JB, TN); Institute for Mathematical and Molecular Biomedicine, King's College London, London, UK (KL, MR, ACCC); Saddle Point Science Ltd, London, UK (MR, ACCC); MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, UK (DF, LB, RK); Department of Oncology, Cancer Research UK and Medical Research Council Oxford Institute for

Radiation Oncology, University of Oxford, Oxford, UK (IDCT, TM, BV); School of Medicine, Cardiff University, Cardiff, UK (RA); Breast Cancer Now Research Unit, Department of Research Oncology, Guy's Hospital King's College London, London, UK (TN); Department of Clinical Biochemistry, Metabolic Research Laboratories, University of Cambridge, Cambridge, UK (KL).

Conflicts of Interest

PRB has received consultancy fees from Oxford Optronix Ltd. TN wishes to declare research funding from AstraZeneca and Daiichi Sankyo. ACCC and MR are directors of Saddle Point Science Ltd. TM was in receipt of honoraria and travel expenses from Merck Serono. RA received travel expenses and honoraria from Merck Serono, Servier and Amgen. DH has stock or other ownership interests in Novartis and Roche. He has also received research funding from Merck Serono and travel, accommodations or expenses from Celgene.

GW, KL, JB, MR-J, DF, JD, FG, IDCT, LB, RK, BV have no conflicts of interest to declare.

Table 1: Patient characteristics of the Full and FRET cohorts.

Covariate	Full Cohort	FRET Training	FRET Validation
N	1630	398	152
TRT = B (%)	815 (50.0)	209 (52.5)	80 (52.6)
CHEMO = XELOX (%)	1070 (65.6)	223 (56.0)	111 (73.0)
Age (at randomisation) (mean (sd))	62.34 (9.79)	63.04 (9.60)	62.77 (9.12)
SEX = Male (%)	1069 (65.6)	278 (69.8)	95 (62.5)
Height (cm) (mean (sd))	170.10 (9.33)	170.14 (9.13)	169.65 (8.92)
Weight (Kg) (mean (sd))	76.05 (15.98)	75.66 (15.63)	78.02 (17.39)
WHO performance status (mean (sd))	0.62 (0.62)	0.58 (0.59)	0.62 (0.65)
Sidedness of primary tumour (%)			
Left-sided	1138 (69.8)	274 (68.8)	103 (67.8)
Right-sided	460 (28.2)	117 (29.4)	48 (31.6)
unknown	32 (2.0)	7 (1.8)	1 (0.7)
TSTAT (%)			
Local recurrence	88 (5.4)	24 (6.0)	18 (11.8)
Resected	865 (53.1)	315 (79.1)	115 (75.7)
Unresected/unresectable	677 (41.5)	59 (14.8)	19 (12.5)
Number of metastatic sites = polymetastatic (>3) (%)	71 (4.4)	17 (4.3)	6 (3.9)
mlivonly = Yes (%)	368 (22.6)	98 (24.6)	34 (22.4)
metscat (%)			
Metachronous	489 (30.0)	159 (39.9)	68 (44.7)
Synchronous	1123 (68.9)	237 (59.5)	84 (55.3)
unknown	18 (1.1)	2 (0.5)	0 (0.0)
MNODE = Yes (%)	720 (44.2)	172 (43.2)	75 (49.3)
Tumour marker: CEA value (mean (sd))	686.99 (2849.05)	374.37 (1310.56)	484.72 (1463.96)
Tumour marker: CA 19-9 value (mean (sd))	2946.00 (13052.42)	546.26 (705.36)	254.50 (152.78)
EREG Cq value, negated (mean (sd))	-3.16 (2.26)	-3.28 (2.27)	-3.10 (2.01)
AREG Cq value, negated (mean (sd))	-2.82 (1.60)	-2.84 (1.58)	-2.73 (1.65)
KRAS (%)			
Mutation	570 (35.0)	165 (41.5)	73 (48.0)
Wild-type	744 (45.6)	225 (56.5)	78 (51.3)
unknown	316 (19.4)	8 (2.0)	1 (0.7)
NRAS (%)			
Mutation	51 (3.1)	17 (4.3)	5 (3.3)
Wild-type	1259 (77.2)	374 (94.0)	147 (96.7)
unknown	320 (19.6)	7 (1.8)	0 (0.0)
MSI (%)			
MSI	45 (2.8)	15 (3.8)	5 (3.3)
Stable	977 (59.9)	314 (78.9)	132 (86.8)
unknown	608 (37.3)	69 (17.3)	15 (9.9)
PIK3CA (%)			
Mutation	156 (9.6)	49 (12.3)	26 (17.1)
Wild-type	1107 (67.9)	334 (83.9)	126 (82.9)
unknown	367 (22.5)	15 (3.8)	0 (0.0)

<i>BRAF</i> (%)			
Mutation	102 (6.3)	29 (7.3)	11 (7.2)
Wild-type	1192 (73.1)	360 (90.5)	141 (92.8)
unknown	336 (20.6)	9 (2.3)	0 (0.0)
ADJCH (%)			
>1m and <6m ago	68 (4.2)	24 (6.0)	8 (5.3)
>6 months ago	261 (16.0)	82 (20.6)	33 (21.7)
No	1218 (74.7)	269 (67.6)	99 (65.1)
Yes (unspecified)	83 (5.1)	23 (5.8)	12 (7.9)
Sum of longest diameter (mean (sd))	106.65 (85.19)	103.88 (81.57)	96.05 (70.83)
Platelet count (mean (sd))	356.31 (132.62)	346.38 (119.65)	329.67 (132.96)
Neutrophil count (mean (sd))	6.29 (3.58)	5.77 (2.64)	5.96 (4.94)
White blood cell count (mean (sd))	8.98 (3.99)	8.51 (3.06)	8.26 (2.92)
Alkaline phosphatase (mean (sd))	191.67 (176.79)	180.77 (171.20)	170.72 (145.04)
PAIN at baseline (CTC grade) (mean (sd))	0.55 (0.74)	0.49 (0.72)	0.38 (0.66)
Anorexia at baseline (CTC grade) (mean (sd))	0.23 (0.54)	0.20 (0.50)	0.12 (0.37)
Vomiting at baseline (CTC grade) (mean (sd))	0.04 (0.24)	0.03 (0.21)	0.02 (0.14)
Lethargy at baseline (CTC grade) (mean (sd))	0.49 (0.65)	0.44 (0.60)	0.38 (0.61)
Haemaglobin at baseline (CTC grade) (mean (sd))	0.25 (0.56)	0.20 (0.47)	0.12 (0.40)
Nail changes at baseline (CTC grade) (mean (sd))	0.01 (0.09)	0.02 (0.14)	0.00 (0.00)

Table 2: Patient characteristics of the 2 discovered latent classes for PFS and OS from the FRET cohort.

Covariate	PFS Class 1	PFS Class 2	p-value*	OS Class 1	OS Class 2	p-value*
n	44	354		62	336	
Treatment arm = B (%)	31 (70.5)	178 (50.3)	0.02	40 (64.5)	169 (50.3)	0.05
CHEMO = XELOX (%)	20 (45.5)	203 (57.3)	0.18	33 (53.2)	190 (56.5)	0.73
Age (at randomisation) (mean (sd))	61.64 (10.65)	63.22 (9.47)	0.30	61.65 (11.71)	63.30 (9.16)	0.21
Sex = Male (%)	29 (65.9)	249 (70.3)	0.67	41 (66.1)	237 (70.5)	0.59
Height (cm) (mean (sd))	170.16 (8.78)	170.13 (9.19)	0.99	169.87 (8.95)	170.19 (9.18)	0.80
Weight (Kg) (mean (sd))	74.40 (12.93)	75.82 (15.94)	0.57	74.92 (14.11)	75.80 (15.91)	0.68
WHO performance status (mean (sd))	0.43 (0.59)	0.60 (0.59)	0.07	0.45 (0.56)	0.61 (0.59)	0.06
Sidedness of primary tumour (%)			0.22			0.93
Left-sided	35 (79.5)	239 (67.5)		44 (71.0)	230 (68.5)	
Right-sided	9 (20.5)	108 (30.5)		17 (27.4)	100 (29.8)	
unknown	0 (0.0)	7 (2.0)		1 (1.6)	6 (1.8)	
Baseline tumour status (%)			0.006			0.01
Local recurrence	7 (15.9)	17 (4.8)		6 (9.7)	18 (5.4)	
Resected	34 (77.3)	281 (79.4)		54 (87.1)	261 (77.7)	
Unresected/unresectable	3 (6.8)	56 (15.8)		2 (3.2)	57 (17.0)	
Number of metastatic sites = polymetastatic (>3) (%)	0 (0.0)	17 (4.8)	0.28	1 (1.6)	16 (4.8)	0.43
Liver-only metastases = Yes (%)	17 (38.6)	81 (22.9)	0.04	24 (38.7)	74 (22.0)	0.008
Timing of metastases (%)			0.88			0.70
Metachronous	18 (40.9)	141 (39.8)		27 (43.5)	132 (39.3)	
Synchronous	26 (59.1)	211 (59.6)		35 (56.5)	202 (60.1)	
unknown	0 (0.0)	2 (0.6)		0 (0.0)	2 (0.6)	
Nodal metastases status = Yes (%)	18 (40.9)	154 (43.5)	0.87	24 (38.7)	148 (44.0)	0.52
Tumour marker: CEA value (mean (sd))	274.76 (641.77)	384.72 (1361.65)	0.67	594.24 (2987.25)	339.65 (774.76)	0.24
Tumour marker: CA 19-9 value (mean (sd))	278.00 (382.52)	586.50 (740.01)	0.49	719.00	538.41 (720.93)	
EREG Cq value, negated (mean (sd))	-2.90 (2.09)	-3.32 (2.29)	0.31	-2.97 (2.55)	-3.33 (2.23)	0.32
AREG Cq value, negated (mean (sd))	-2.65 (1.59)	-2.86 (1.58)	0.46	-2.69 (1.53)	-2.86 (1.59)	0.48
KRAS mutation status (%)			0.39			0.54
Mutation	14 (31.8)	151 (42.7)		22 (35.5)	143 (42.6)	
Wild-type	29 (65.9)	196 (55.4)		39 (62.9)	186 (55.4)	
unknown	1 (2.3)	7 (2.0)		1 (1.6)	7 (2.1)	

<i>NRAS</i> mutation status (%)			0.50			0.46
Mutation	1 (2.3)	16 (4.5)		2 (3.2)	15 (4.5)	
Wild-type	43 (97.7)	331 (93.5)		60 (96.8)	314 (93.5)	
unknown	0 (0.0)	7 (2.0)		0 (0.0)	7 (2.1)	
Microsatellite stability status (%)			0.53			0.78
MSI	2 (4.5)	13 (3.7)		2 (3.2)	13 (3.9)	
Stable	37 (84.1)	277 (78.2)		51 (82.3)	263 (78.3)	
unknown	5 (11.4)	64 (18.1)		9 (14.5)	60 (17.9)	
<i>PIK3CA</i> mutation status (%)			0.37			0.009
Mutation	6 (13.6)	43 (12.1)		14 (22.6)	35 (10.4)	
Wild-type	38 (86.4)	296 (83.6)		48 (77.4)	286 (85.1)	
unknown	0 (0.0)	15 (4.2)		0 (0.0)	15 (4.5)	
<i>BRAF</i> mutation status (%)			0.54			0.89
Mutation	5 (11.4)	24 (6.8)		4 (6.5)	25 (7.4)	
Wild-type	38 (86.4)	322 (91.0)		57 (91.9)	303 (90.2)	
unknown	1 (2.3)	8 (2.3)		1 (1.6)	8 (2.4)	
Adjuvant chemotherapy (%)			0.71			0.83
>1m and <6m ago	3 (6.8)	21 (5.9)		4 (6.5)	20 (6.0)	
>6 months ago	10 (22.7)	72 (20.3)		13 (21.0)	69 (20.5)	
No	27 (61.4)	242 (68.4)		43 (69.4)	226 (67.3)	
Yes (unspecified)	4 (9.1)	19 (5.4)		2 (3.2)	21 (6.2)	
Sum of longest diameter (mean (sd))	81.66 (74.30)	106.67 (82.11)	0.05	68.39 (52.90)	110.49 (84.28)	<0.001
Platelet count (mean (sd))	348.34 (109.90)	346.13 (120.95)	0.91	341.32 (99.13)	347.31 (123.18)	0.72
Neutrophil count (mean (sd))	4.76 (1.69)	5.90 (2.71)	0.007	5.10 (1.73)	5.90 (2.76)	0.03
White blood cell count (mean (sd))	7.50 (2.15)	8.63 (3.14)	0.02	7.98 (2.28)	8.61 (3.18)	0.14
Alkaline phosphatase (mean (sd))	171.11 (207.48)	181.98 (166.44)	0.69	140.52 (150.16)	188.22 (174.00)	0.04
PAIN at baseline (CTC grade) (mean (sd))	0.32 (0.60)	0.51 (0.74)	0.09	0.32 (0.65)	0.52 (0.73)	0.05
Anorexia at baseline (CTC grade) (mean (sd))	0.09 (0.29)	0.21 (0.51)	0.13	0.16 (0.45)	0.20 (0.50)	0.53
Vomiting at baseline (CTC grade) (mean (sd))	0.00 (0.00)	0.03 (0.22)	0.31	0.00 (0.00)	0.04 (0.23)	0.22
Lethargy at baseline (CTC grade) (mean (sd))	0.34 (0.57)	0.45 (0.60)	0.24	0.32 (0.57)	0.46 (0.60)	0.09
Haemoglobin at baseline (CTC grade) (mean (sd))	0.09 (0.29)	0.22 (0.49)	0.09	0.10 (0.30)	0.22 (0.50)	0.05
Nail changes at baseline (CTC grade) (mean (sd))	0.00 (0.00)	0.02 (0.15)	0.31	0.00 (0.00)	0.02 (0.15)	0.22
FRET: HER2-HER3 FRET efficiency (mean (sd))	0.01 (0.02)	0.02 (0.02)	0.006	0.01 (0.02)	0.02 (0.03)	0.10
FRET x HER3 intensity (mean (sd))	0.26 (1.37)	0.66 (1.81)	0.15	0.52 (1.26)	0.64 (1.85)	0.63

*Chi-squared test for categorical values or ANOVA for continuous variables, all two-sided.

FIGURES

Figure 1




Figure 1: CONSORT diagram of patient selection and analysis flow for the FRET

cohorts that were subject to dimer imaging and the Full Cohort. Patients excluded at

the TMA and Image quality control stage had insufficient tissue remaining on the slide or the

tissue was of bad quality (e.g. folded) or the donor and donor-acceptor areas could not be

matched. Class membership revealed by the Latent Class Analysis on the FRET cohort of

398 was used to train a class membership signature, which was tested in the validation set

of 152 patients. The concordance between the latent class analysis on the FRET and Full

cohorts was assessed in a class overlap comparison. FS = formol saline. Treatment arms:

A=Oxaliplatin and Fluoropyrimidine Chemotherapy, B=A+Cetuximab, C=Intermittent

Chemotherapy.

Figure 2




Figure 2: Detection of HER2-HER3 dimerization by FLIM. Pseudo colour FRET efficiency maps indicate degree of HER2-HER3 interaction. Scale bar = 50 μm .

Figure 3




Figure 3: Multivariate latent class analysis (LCA) of the FRET cohort. A,B) Tables of covariate associated hazard ratios for the 2 discovered classes. For those in Class 1, Treatment Arm B (cetuximab) was protective (for OS, squares). For those in Class 2, a high FRET HER2-HER3 dimer score was protective (circles). **C,D)** Survival curves split by class and treatment arm to show potential prognostic and predictive value, for OS and PFS. Log rank p-values for prognostic and predictive splits show that FRET-based LCA with 398

patients has a clear prognostic (log-rank $p < 0.001$) and a potential predictive value:
Cetuximab (TRT arm B) was effective for patients in OS Class 1 (log-rank $p = 0.05$). E,F)
Survival curves split by class and FRET efficiency. The statistically significant HR associated
with FRET in Class 2 is demonstrated. Patients in Class 2 have a better outcome if their
HER2-HER3 FRET Efficiency is in the upper tertile (PFS log-rank $p < 0.001$, OS log-rank
 $p = 0.02$). All statistical tests were two-sided.

Figure 4




Figure 4: Latent Class Analysis testing for similar classes within the full cohort using baseline covariates and OS. A) Table of covariates of statistical significance. B) Kaplan-Meier plot split by class and treatment arm. The 3 classes are prognostic (log-rank $p < 0.001$). Class 3 predicts a treatment response (log-rank $p < 0.001$). C) LCA OS Class membership comparison between the 398 FRET cohort (2 classes, **Figure 3) and the overlap with the full cohort (3 classes). A randomised permutations test indicates a non-random overlap of patients with the class sets. All statistical tests were two-sided.**

Figure 5




Figure 5: Mixed covariate class prediction signatures with and without FRET. A) Table of selected covariates in the with-FRET signature, ranked by importance. The Weight indicates how each covariate should be combined to form a class prediction score, with a

constant that gives the signature a zero mean. Class 2 is associated with a signature score > -0.335 . High FRET favours Class 2 because of its positive weight. **B)** ROC curve for the class prediction score showing its performance in predicting the class of the 398 patients in the training set (Specificity=0.677, Sensitivity=0.708) and the optimal class threshold (-0.335). **C,D)** Survival curves split by class and treatment arm for the training set and independent validation set, respectively. **E)** Table of selected covariates in the without-FRET signature. **F,G)** Survival curves split by class for the with- and without-FRET signatures applied to the 152 validation set. FRET provides information that splits the classes (log rank p-value=0.04).

REFERENCES

1. Van Cutsem E, Köhne C-H, Hitre E, *et al.* Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. *New England Journal of Medicine* 2009;360(14):1408-1417.
2. Heinemann V, von Weikersthal LF, Decker T, *et al.* FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. *The Lancet Oncology*;15(10):1065-1075.
3. Venook AP, Niedzwiecki D, Lenz H-J, *et al.* CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). *Journal of Clinical Oncology* 2014;32:5s(suppl; abstr LBA3).
4. Price TJ, Townsend AR, Peeters M. FOLFIRI with cetuximab or bevacizumab: FIRE-3. *The Lancet Oncology* 2014;15(13):e582-e583.
5. Al-Shamsi HO, Alhazzani W, Wolff RA. Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. *Journal of gastrointestinal oncology* 2015;6(3):314-321.
6. Douillard JY, Siena S, Cassidy J, *et al.* Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2010;28(31):4697-705.
7. Jonker DJ, Karapetis CS, Harbison C, *et al.* Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. *Br J Cancer* 2014;110(3):648-55.
8. Seligmann JF, Elliott F, Richman SD, *et al.* Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. *JAMA oncology* 2016; 10.1001/jamaoncol.2015.6065.
9. Sugai T, Habano W, Jiao Y-F, *et al.* Analysis of Molecular Alterations in Left- and Right-Sided Colorectal Carcinomas Reveals Distinct Pathways of Carcinogenesis : Proposal for New Molecular Profile of Colorectal Carcinomas. *The Journal of molecular diagnostics : JMD* 2006;8(2):193-201.
10. Toyota M, Ohe-Toyota M, Ahuja N, *et al.* Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. *Proceedings of the National Academy of Sciences of the United States of America* 2000;97(2):710-715.
11. Koestler DC, Li J, Baron JA, *et al.* Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. *Mod Pathol* 2014;27(1):145-155.
12. Missiaglia E, Jacobs B, D'Ario G, *et al.* Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. *Annals of Oncology* 2014;25(10):1995-2001.
13. Sanz-Pamplona R, Cordero D, Berenguer A, *et al.* Gene Expression Differences between Colon and Rectum Tumors. *Clinical Cancer Research* 2011;17(23):7303-7312.
14. Yamauchi M, Morikawa T, Kuchiba A, *et al.* Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. *Gut* 2012;61(6):847-854.

15. Perrone F, Lampis A, Orsenigo M, *et al.* PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. *Ann Oncol* 2009;20(1):84-90.
16. Saridaki Z, Tzardi M, Papadaki C, *et al.* Impact of KRAS, BRAF, PIK3CA mutations, PTEN, AREG, EREG expression and skin rash in ≥ 2 line cetuximab-based therapy of colorectal cancer patients. *PLoS One* 2011;6(1):e15980.
17. Sartore-Bianchi A, Di Nicolantonio F, Nichelatti M, *et al.* Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. *PLoS One* 2009;4(10):e7287.
18. Karapetis CS, Jonker D, Daneshmand M, *et al.* PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. *Clin Cancer Res* 2014;20(3):744-53.
19. De Roock W, Claes B, Bernasconi D, *et al.* Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 2010;11(8):753-62.
20. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. *Nature reviews Molecular cell biology* 2001;2(2):127-37.
21. Holbro T, Beerli RR, Maurer F, *et al.* The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. *Proc Natl Acad Sci U S A* 2003;100(15):8933-8.
22. Bosch-Vilaro A, Jacobs B, Pomella V, *et al.* Feedback activation of HER3 attenuates response to EGFR inhibitors in colon cancer cells. *Oncotarget* 2017;8(3):4277-4288.
23. Weitsman G, Barber PR, Nguyen LK, *et al.* HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. *Oncotarget* 2016;7(32):51012-51026.
24. Fruhwirth GO, Fernandes LP, Weitsman G, *et al.* How Forster resonance energy transfer imaging improves the understanding of protein interaction networks in cancer biology. *Chemphyschem* 2011;12(3):442-61.
25. Ng T, Squire A, Hansra G, *et al.* Imaging protein kinase Calpha activation in cells. *Science* 1999;283(5410):2085-9.
26. Parsons M, Ng T. Intracellular coupling of adhesion receptors: molecular proximity measurements. *Methods Cell Biol* 2002;69:261-78.
27. Kelleher MT, Fruhwirth G, Patel G, *et al.* The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients. *Target Oncol* 2009;4(3):235-52.
28. Tao JJ, Castel P, Radosevic-Robin N, *et al.* Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. *Sci Signal* 2014;7(318):ra29.
29. Weitsman G, Lawler K, Kelleher MT, *et al.* Imaging tumour heterogeneity of the consequences of a PKCalpha-substrate interaction in breast cancer patients. *Biochem Soc Trans* 2014;42(6):1498-505.
30. Coban O, Zanetti-Dominguez LC, Matthews DR, *et al.* Effect of Phosphorylation on EGFR Dimer Stability Probed by Single-Molecule Dynamics and FRET/FLIM. *Biophys J* 2015;108(5):1013-26.
31. Adams RA, Meade AM, Seymour MT, *et al.* Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *The Lancet Oncology* 2011;12(7):642-653.

32. Rowley M, Garmo H, Van Hemelrijck M, *et al.* A latent class model for competing risks. *Statistics in Medicine* 2017; 10.1002/sim.7246:10.1002/sim.7246.
33. Grigoriadis A, Gazinska P, Pai T, *et al.* Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node-positive breast cancers. *The Journal of Pathology: Clinical Research* 2018;4(1):39-54.
34. Häggström C, Hemelrijck MV, Garmo H, *et al.* Heterogeneity in risk of prostate cancer: A Swedish population-based cohort study of competing risks and Type 2 diabetes mellitus. *International Journal of Cancer* 2018;143(8):1868-1875.
35. Barber PR, Tullis ID, Pierce GP, *et al.* The Gray Institute 'open' high-content, fluorescence lifetime microscopes. *J Microsc* 2013;251(2):154-67.
36. Barber PR, Ameer-Beg SM, Gilbey J, *et al.* Multiphoton time-domain FLIM: Practical application to protein-protein interactions using global analysis. *J. R. Soc. Interface* 2009;6:S93-S105.
37. Barber PR, Ameer-Beg SM, Gilbey J, *et al.* Global and pixel kinetic data analysis for FRET detection by multi-photon time-domain FLIM. *Proc SPIE* 2005;5700:171-181.
38. Rowley MI, Coolen ACC, Vojnovic B, *et al.* Robust Bayesian Fluorescence Lifetime Estimation, Decay Model Selection and Instrument Response Determination for Low-Intensity FLIM Imaging. *PLOS ONE* 2016;11(6):e0158404.
39. Barber PR, Tullis IDC, Rowley MI, *et al.* The Gray Institute open microscopes applied to radiobiology and protein interaction studies. *Proc. SPIE* 2014;8949:89490D–17.
40. Weitsman G, Barber PR, Nguyen LK, *et al.* HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status. *Oncotarget* 2016;7(32):51012-51026.
41. Tveit KM, Guren T, Glimelius B, *et al.* Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study. *Journal of Clinical Oncology* 2012;30(15):1755-1762.
42. Bokemeyer C, Bondarenko I, Makhson A, *et al.* Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009;27(5):663-71.
43. Hutchinson RA, Adams RA, McArt DG, *et al.* Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer. *Journal of Translational Medicine* 2015;13:217.
44. Chung KY, Shia J, Kemeny NE, *et al.* Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry. *Journal of Clinical Oncology* 2005;23(9):1803-1810.
45. Jura N, Shan Y, Cao X, *et al.* Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. *Proc Natl Acad Sci U S A* 2009;106(51):21608-13.
46. Aertgeerts K, Skene R, Yano J, *et al.* Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. *J Biol Chem* 2011;286(21):18756-65.
47. Zhang Q, Park E, Kani K, *et al.* Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. *Proc Natl Acad Sci U S A* 2012;109(33):13237-42.
48. Komurasaki T, Toyoda H, Uchida D, *et al.* Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. *Oncogene* 1997;15(23):2841-8.
49. Shelly M, Pinkas-Kramarski R, Guarino BC, *et al.* Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. *J Biol Chem* 1998;273(17):10496-505.

50. Meric-Bernstam F, Hurwitz H, Raghav KPS, *et al.* Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. *Lancet Oncol* 2019;20(4):518-530.
51. Harle A, Salleron J, Perkins G, *et al.* Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. *Br J Cancer* 2015;113(4):680-5.
52. Er EE, Mendoza MC, Mackey AM, *et al.* AKT facilitates EGFR trafficking and degradation by phosphorylating and activating PIKfyve. *Sci Signal* 2013;6(279):ra45.
53. Ng T, Flores-Borja F, Alfano G, *et al.* The use of exosome and immune profiling to analyze a phase 2 study on the addition of patritumab or placebo to cetuximab and a platinum agent for recurrent / metastatic head and neck cancer (R/M HNSCC) patients. *Journal of Clinical Oncology* 2018;36(15_suppl):6043-6043.